Targeted Cancer Therapies Show Promise in Early-Stage Breast Cancer and beyond
Table of Contents
New clinical trial data presented this week offers a important boost too the field of oncology, demonstrating the effectiveness of conjugated antibodies – also known as ADCs – in treating a wider range of cancers and, crucially, showing potential for earlier intervention in breast cancer treatment.
A wave of optimism swept through the European Society of Medical Oncology Congress in Berlin as researchers unveiled results from three pivotal clinical trials. The data, shared with over 30,000 attendees, highlights the effectiveness of antibody-drug conjugates (ADCs), a type of targeted therapy that is revolutionizing cancer treatment.
ADCs are designed to specifically target cancer cells.As Dr. Zaman Khalil, a medical oncologist and head of the CHUV Breast Centre in Lausanne, explains, “We can imagine them as missiles, they precisely locate their target and deliver chemotherapy.” This targeted approach aims to maximize the impact on the tumor while minimizing damage to healthy cells – a long-sought goal in oncology.
While these treatments are administered via infusion, similar to customary chemotherapy, the specialist cautions that tolerance remains comparable, meaning undesirable side effects still require careful monitoring.
Expanding Applications: From Metastatic Disease to Early Intervention
Historically, novel cancer treatments are first evaluated in patients with metastatic disease, where effectiveness and tolerance can be assessed more rapidly. The emerging data now suggests a role for these therapies much earlier in the treatment pathway, especially in certain breast cancers.
One trial focused on HER2-positive breast cancers, a subtype representing approximately 15% of all breast cancer cases. The results are particularly striking: using an ADC to prevent relapse after initial treatment nearly halved the risk of recurrence and metastasis. “With usual treatment, a little more than 16% of patients relapsed at three years; with the conjugated antibody, we are less than 8%,” Dr. Khalil stated.
swiss approval Pathway and future Outlook
In Switzerland, a conjugated antibody targeting HER2 is already approved for use in metastatic breast cancer.Extending its use to earlier stages of the disease will require evaluation by regulatory authorities. “We can first expect acceptances on a case-by-case basis if the files are convincing,” the clinician indicated.
Beyond breast cancer,the trials also demonstrated positive results in bladder cancer,particularly for patients ineligible for conventional chemotherapy. The tested ADC reduced the risk of relapse by approximately 60% and improved overall survival. Currently, conjugated antibodies are approved for use in several cancer types, including bladder, lung, stomach, and ovarian cancers, contingent on the presence of the specific marker targeted by each drug.
Overcoming Resistance and Refining the Approach
Despite the promising results, researchers acknowledge that challenges remain. As with traditional chemotherapies, cancer cells can develop resistance to ADCs. Current research is focused on two key areas: improving the precision of antibody guidance to ensure even more accurate targeting, and diversifying the chemotherapy agents attached to the antibodies.
A new generation study underway at the CHUV is comparing a double-seeking ADC – designed to bind to multiple targets on the tumor cell – to standard chemotherapy in patients with metastatic triple-negative breast cancer.The objective is to enhance attachment to the tumor and bolster effectiveness.
The Enduring Importance of Early detection
Even with these advancements in precision medicine, the importance of early cancer detection remains paramount. “The best treatment is the one you don’t need,” Dr. Khalil emphasized. Regular screening mammography between the ages of 50 and 75 significantly improves prognosis in breast cancer by identifying smaller tumors that require less aggressive treatment.
This article is adapted from a radio report by Stéphane Délétroz for CQFD, featuring an interview with Dr. Zaman khalil, medical oncologist and medical manager of the Breast Center at CHUV, and adapted for the web by Adriano koch.
